Why CLDN18.2 Is a Compelling Oncology Target
Claudin 18.2 (CLDN18.2) is a 27.8 kDa four-transmembrane-domain tight junction protein whose expression in normal tissue is restricted exclusively to gastric epithelium. In gastric cancer (GC) and pancreatic ductal adenocarcinoma (PDAC), disruption of tight junction architecture exposes CLDN18.2’s extracellular loops on the tumor cell surface — a pharmacological vulnerability that does not exist in healthy non-gastric tissue. This tumor-selective surface presentation is the central rationale for the entire CLDN18.2-directed pipeline.
The target’s prevalence in GC is substantial: an immunohistochemical study found that 81.8% of GC patients were CLDN18.2-positive, with a statistically significant positive correlation between CLDN18.2 expression and peptide-specific T cell reactivity (p = 0.002). This immunogenic surface presentation supports not just antibody-based approaches but also cellular immunotherapy strategies. According to WIPO, tight junction proteins have become an increasingly active class of oncology patent targets over the past decade, reflecting their structural accessibility and tissue-restricted expression profiles.
Claudin 18.2 (CLDN18.2) is expressed in 81.8% of gastric cancer patients by immunohistochemistry, with a statistically significant positive correlation between CLDN18.2 expression and peptide-specific T cell reactivity (p = 0.002), based on a study from Nanjing University’s Drum Tower Hospital.
In PDAC — a disease with near-100% mortality, early metastatic spread, and resistance to chemoradiotherapy — CLDN18.2’s expression has been confirmed through analysis of The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Gene Expression Omnibus (GEO), and European Genome-phenome Archive (EGA) databases. A 2022 analysis from Shaanxi Provincial People’s Hospital concluded that CLDN18.2 is a candidate target for PDAC treatment, providing the molecular rationale for deploying zolbetuximab in this indication. A 2023 retrospective cohort study of 68 resected PDAC patients at Suleyman Demirel University Hospital further examined CLDN18.2 and HER2 co-expression using archived surgical pathology, providing real-world patient-level data to inform clinical selection criteria — though no statistically significant prognostic correlation was identified in that cohort.
CLDN18.2 (Claudin 18, splice variant 2) is a 27.8 kDa protein with four transmembrane domains and two extracellular loops. In normal tissue, it is detectable exclusively in the stomach by RT-PCR and immunohistochemistry. Aberrant surface exposure in gastric and pancreatic adenocarcinoma — caused by disruption of tight junction architecture in transformed epithelium — makes the extracellular loops accessible to antibody-based therapies, a property absent in healthy non-gastric tissue.
The Patent Landscape: Astellas Dominance and White Spaces
Astellas Pharma Inc. controls the dominant CLDN18.2 patent estate through its acquisition of Ganymed Pharmaceuticals AG, with at least five active patent records spanning IL, EP, SG, and US jurisdictions — all tracing to PCT/EP2014/000433. The core claim across these filings is a combination framework: anti-CLDN18.2 antibodies paired with chemotherapy for pancreatic cancer and its metastases. TRON-Translationale Onkologie at Johannes Gutenberg University Mainz holds a co-filed US patent covering combination therapy for pancreatic adenocarcinoma under the same PCT priority.
The mechanistic basis across all Astellas/Ganymed filings is consistent: anti-CLDN18.2 antibodies bind the first extracellular loop of CLDN18.2, inducing antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct growth inhibition in CLDN18.2-expressing tumor cells. The continuation/divisional structure of the Astellas US patent (2021, active), tracing through multiple national stage entries since 2014, signals sustained commercial investment consistent with an active clinical program rather than shelf IP.
Astellas Pharma Inc. controls at least five active CLDN18.2 patent records across IL, EP, SG, and US jurisdictions following its acquisition of Ganymed Pharmaceuticals AG, all tracing to PCT/EP2014/000433 and covering anti-CLDN18.2 antibody combination therapy for gastric cancer and pancreatic adenocarcinoma.
Critically, no retrieved record in this dataset describes a CLDN18.2-specific ADC patent. Despite the robustness of the anti-CLDN18.2 antibody IP estate, the ADC format — combining a CLDN18.2-binding antibody with a cytotoxic payload via a chemical linker — appears to represent an unoccupied IP white space, pending freedom-to-operate analysis against the foundational Astellas/Ganymed antibody claims. Agensys (an Astellas subsidiary) does hold pending ADC patents in IL and SG for cancer treatment using antibodies binding 191P4D12 proteins, covering patients with prior PD-1/PD-L1 therapy exposure, demonstrating organizational ADC capability adjacent to the CLDN18.2 estate. According to the EPO, ADC patent filings in oncology have grown substantially in recent years, making the absence of CLDN18.2-specific ADC claims a notable gap in this landscape.
Map the full CLDN18.2 patent estate and identify freedom-to-operate opportunities with PatSnap Eureka.
Explore CLDN18.2 Patent Data in PatSnap Eureka →Therapeutic Modalities: From Monoclonal Antibodies to CAR-T
The CLDN18.2 pipeline spans four distinct therapeutic modalities, each at a different stage of development. Zolbetuximab (claudiximab; IMAB362) — the most clinically advanced — is a first-in-class anti-CLDN18.2 monoclonal antibody described in a 2017 clinical review from Maimonides Medical Center as specifically targeting tumor-expressed CLDN18.2 and differentiated from HER2-directed therapy. Phase II/III-level clinical investigation for antibody monotherapy and combination regimens was underway at the time of that publication.
“In gastric cancer, 81.8% of patients were CLDN18.2-positive by IHC, with a statistically significant positive correlation between CLDN18.2 expression and peptide-specific T cell reactivity (p = 0.002) — substantiating its immunogenic surface presentation.”
Peptide-Based T Cell Immunotherapy
Investigators at Nanjing University’s Drum Tower Hospital identified five HLA-A*0201-restricted and seven HLA-A*1101-restricted T cell epitopes of CLDN18.2. PBMCs stimulated with CLDN18.2 peptides showed progressive anti-tumor activity and elevated cytokine secretion compared to unstimulated controls in vitro, positioning CLDN18.2 as a viable target for peptide vaccine and adoptive T cell approaches in GC. This work remains at the preclinical/translational stage.
CAR-T Cell Therapy with NKG2D Arming
Investigators at Fudan University’s School of Pharmacy developed CLDN18.2-targeting CAR-T cells armored with novel synthetic NKG2D receptors containing DAP10 and DAP12 signaling domains. The design addresses a recognized limitation of single-target CAR-T in solid tumors: heterogeneous CLDN18.2 expression. By combining CLDN18.2-directed cytotoxicity with NKG2D ligand (NKG2DL)-mediated killing — NKG2DLs being broadly expressed on GI cancers but absent on normal tissues — the construct creates a bimodal cellular immunotherapy architecture. Preclinical data from cell line models support IND-enabling work, though no specific clinical trial enrollment was reported in the retrieved text.
Adjacent Claudin-Family Approaches
Investigators at the German Cancer Consortium (DKFZ, Heidelberg) described a claudin-targeted suicide gene therapy using Clostridium perfringens enterotoxin (CPE), which selectively binds claudin-3 and claudin-4 — both upregulated in PDAC — inducing selective cytotoxicity through pore formation in vitro and necrosis in vivo in patient-derived xenograft models. While this approach targets claudin-3/4 rather than CLDN18.2, it establishes proof-of-concept for claudin-family proteins as oncoleaking therapeutic targets in pancreatic cancer, providing mechanistic context for the broader CLDN18.2-directed strategy.
Fudan University researchers developed CLDN18.2-targeting CAR-T cells armored with synthetic NKG2D receptors containing DAP10 and DAP12 signaling domains, designed to overcome heterogeneous CLDN18.2 expression in solid tumors by combining CLDN18.2-directed cytotoxicity with NKG2D ligand-mediated killing — NKG2D ligands being broadly expressed on GI cancers but absent on normal tissues.
ADC and Bispecific Approaches: Evidence and Opportunity
No retrieved record describes a CLDN18.2-specific ADC patent or standalone clinical paper — yet the mechanistic template for deploying ADC payloads against GI surface antigens in PDAC is well-established in adjacent literature. A 2022 review from Tianjin University of Traditional Chinese Medicine details the ADC landscape in advanced gastric cancer, describing the standard architecture (monoclonal antibody + chemical linker + cytotoxic payload) and framing CLDN18.2-targeting as part of the broader precision therapy push in GC.
Two preclinical ADC programs in PDAC provide directly relevant mechanistic templates. An anti-glypican-1 (GPC-1) monoclonal antibody conjugated to monomethyl auristatin F (MMAF) demonstrated potent anti-tumor activity in BxPC-3 and T3M-4 PDAC xenograft and patient-derived tumor models, as reported by investigators at Japan’s National Institute of Biomedical Innovation. Separately, the c-MET-targeting ADC SHR-A1403 significantly inhibited proliferation, migration, and invasion, and induced apoptosis and cell cycle arrest in PDAC preclinical models (Shanghai Jiao Tong University, 2021). Both programs validate the ADC delivery concept for GI surface antigens and inform linker and payload selection strategies applicable to future CLDN18.2-ADC development. As noted by the NIH, ADC payloads such as auristatins and maytansinoids have demonstrated activity across multiple solid tumor types when conjugated to high-affinity targeting antibodies.
Despite a dense Astellas/Ganymed patent estate covering anti-CLDN18.2 antibody combination therapy, no retrieved record describes a CLDN18.2-specific ADC patent or clinical paper. Developers with proprietary linker-payload technologies and CLDN18.2-binding antibody moieties may find this an underprotected format — subject to freedom-to-operate analysis against foundational antibody claims.
Bispecific Signals in the Dataset
No retrieved result directly claims a CLDN18.2 × PD-1/PD-L1 bispecific antibody construct. However, the dataset contains multiple signals that collectively indicate this is a scientifically plausible and underprotected IP space. The NKG2D-armored CLDN18.2 CAR-T data from Fudan University represents an emerging bispecific cellular immunotherapy architecture. A systematic review and meta-analysis of PD-1 and PD-L1 inhibitors in metastatic gastric and gastroesophageal junction adenocarcinoma (Northern Ontario School of Medicine, 2021) and a combination therapy review for PDAC (Zhejiang University School of Medicine, 2022) both document checkpoint inhibitor activity in these indications. A separate study from Lanzhou University Second Hospital (2022) demonstrated that anti-uPAR monoclonal antibody plus anti-PD-1 combination achieved synergistic tumor control in diffuse-type gastric cancer. Taken together, these signals suggest that a CLDN18.2 × checkpoint bispecific would represent a logical next-generation direction — though no such specific construct is directly evidenced in this dataset.
Identify bispecific antibody patent gaps and combination therapy opportunities across the CLDN18.2 pipeline with PatSnap Eureka.
Analyse CLDN18.2 Bispecific Opportunities →Patient Stratification: A Critical Bottleneck
Retrieved clinical and translational data highlight heterogeneous CLDN18.2 expression in both PDAC and GC, with co-expression of HER2 and histological subtype (diffuse vs. intestinal) identified as key stratification variables. The 2023 PDAC cohort study from Suleyman Demirel University examined CLDN18.2 and HER2 co-expression in 68 resected specimens, supporting the utility of dual-biomarker stratification in patient selection — even though no statistically significant prognostic correlation was identified in that cohort alone. A 2022 paper from the Cancer Institute Hospital of the Japanese Foundation for Cancer Research described precision medicine approaches in diffuse-type gastric cancer, further underscoring histological subtype as a selection variable. Drug developers should plan companion diagnostic development in parallel with therapeutic IND filing. The FDA has increasingly required companion diagnostic co-development for targeted oncology agents, a regulatory expectation that applies directly to CLDN18.2-directed programs given expression heterogeneity across both indications.
A 2022 database analysis using TCGA, GTEx, GEO, and EGA data, conducted by Shaanxi Provincial People’s Hospital, concluded that CLDN18.2 is a candidate therapeutic target for pancreatic ductal adenocarcinoma and provided the molecular rationale for deploying zolbetuximab (claudiximab; IMAB362) in this indication.
Strategic Implications for Drug Developers
IP concentration in CLDN18.2 is high and geographically broad: Astellas Pharma, through its Ganymed acquisition, controls an active, multi-jurisdictional patent estate on anti-CLDN18.2 combination therapy covering both gastric cancer and PDAC. Entities seeking to develop CLDN18.2-directed ADCs or bispecifics must navigate this foundational IP — particularly the antibody-binding claims that cover the first extracellular loop of CLDN18.2 across multiple national jurisdictions.
Chinese academic institutions are emerging as key innovation contributors in the cellular immunotherapy space. Multiple retrieved papers from Fudan University, Nanjing University, and Shanghai Jiao Tong University describe advanced preclinical CLDN18.2 cellular therapy and ADC-adjacent approaches, suggesting that Chinese biotech and academic spinouts may generate competitive IP and clinical programs within the near term. This geographic diversification of innovation activity mirrors broader trends in oncology drug discovery tracked by WHO and international patent authorities.
“Despite the robustness of the anti-CLDN18.2 antibody IP estate, no retrieved record describes a CLDN18.2-specific ADC patent — a potential opportunity for developers with proprietary linker-payload technologies, pending freedom-to-operate analysis.”
The strategic landscape can be summarised across five dimensions:
- IP navigation: The Astellas/Ganymed/TRON patent estate is the primary freedom-to-operate challenge for any CLDN18.2-directed program. Antibody moiety claims are the central constraint; linker-payload innovations may offer design-around pathways.
- ADC white space: The absence of CLDN18.2-specific ADC patents in this dataset represents a potential first-mover opportunity, with GPC-1 MMAF-ADC and c-MET SHR-A1403 data providing mechanistic precedent for PDAC ADC delivery.
- Bispecific underprotection: NKG2D-armored CAR-T and checkpoint combination signals collectively indicate that bispecific or combination immunotherapy formats targeting CLDN18.2 alongside a co-stimulatory or checkpoint axis are scientifically plausible and represent an underprotected IP space in this dataset.
- Patient selection: Heterogeneous CLDN18.2 expression in PDAC and GC, combined with HER2 co-expression data and histological subtype stratification, means companion diagnostic development should be planned in parallel with IND filing.
- Competitive intelligence: Chinese academic institutions (Fudan, Nanjing, Shanghai Jiao Tong) are generating preclinical cellular therapy and ADC-adjacent data at pace, signalling near-term competitive IP risk from this geography.
It is important to note that this analysis is derived from a limited set of patent and literature records retrieved across targeted searches. It represents a snapshot of innovation signals within this dataset only and should not be interpreted as a comprehensive view of the full clinical pipeline or regulatory landscape. Comprehensive freedom-to-operate analysis requires full patent family searches beyond the records described here. PatSnap’s drug discovery intelligence platform provides access to over 2 billion data points across 120+ countries to support such analysis, and the pharmaceutical intelligence suite enables target-level patent landscaping at scale.